Clinical Trial Update: Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the efficacy and safety of 4.5 mg PEG-rhG-CSF per cycle to prevent neutropenia after intensive chemotherapy in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neutropenia

Drugs mentioned

• PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Peking University | Conditions: Breast Cancer, Neutropenia | Phase 4 | Status: COMPLETED